Reviews18

Retatrutide Phase 3 Results: 28.3% Weight Loss in TRIUMPH-1 (2026)

Published May 21, 2026Updated October 19, 2026
Quick Brief

Retatrutide Phase 3 results (May 2026 TRIUMPH-1): 28.3% weight loss at 80 weeks, up to 30.3% at 104 weeks, full safety + dose data and what's next.

Retatrutide Phase 3 Results: 28.3% Weight Loss in TRIUMPH-1 (2026)
Retatrutide - R-30

Procurement

Retatrutide - R-30

In StockShips from USA
$125.00$250.00
Get R-30

Retatrutide Phase 3 results are in. Eli Lilly announced positive topline data from TRIUMPH-1 today (May 21, 2026), the first registrational Phase 3 obesity trial for retatrutide. Participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks (efficacy estimand; 25.0% counting everyone randomized). Full results were later published in the New England Journal of Medicine on September 29, 2026. Those with a starting BMI of 35 or higher who continued on the drug lost up to 30.3% (an average 85.0 lbs) at 104 weeks. The dose-escalation 4 mg arm hit 19.0% weight loss with a discontinuation rate lower than placebo. Here's what the data shows and what it means for the FDA approval timeline.

Last Updated October 19, 2026
28.3%Weight loss at 12 mg, 80 weeks
30.3%Weight loss at 12 mg, 104 weeks (extension)
85.0 lbsAverage absolute loss in 104-week extension
2,339Participants randomized 1:1:1:1

🔑 Key Takeaways

  • All three doses met primary and key secondary endpoints. 4 mg, 9 mg, and 12 mg vs placebo across an 80-week primary period.
  • 12 mg dose: 28.3% body-weight loss (70.3 lbs from a 248.5 lb baseline; efficacy estimand). 62.5% of participants achieved at least 25% loss; 45.3% achieved at least 30%; 27.2% achieved at least 35%.
  • 104-week extension was even stronger. Participants with baseline BMI of 35 or higher who stayed on the highest tolerated dose lost 30.3% (85.0 lbs) at two years. Weight loss continued past the 80-week mark rather than plateauing.
  • 4 mg dose is a real option. 19.0% weight loss with just one escalation step and a discontinuation rate (4.1%) lower than placebo (4.9%). Useful for patients who don't tolerate higher doses.
  • 65.3% of participants on 12 mg dropped below BMI 30 at 80 weeks, falling out of the obesity classification. 37.5% of those who started with class 3 obesity (BMI of 40 or higher) also crossed below 30.
  • Safety: GI side effects dominate, as expected. Nausea 42.4% at 12 mg, vomiting 25.3%, diarrhea 32.0%. Dysesthesia (skin tingling) 12.5% at 12 mg. Discontinuation due to adverse events: 11.3% at 12 mg.
  • Cardiometabolic improvements: Significant reductions in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP).

Today's release is the biggest single Phase 3 obesity readout for retatrutide so far. Combined with the December 2025 TRIUMPH-4 trial (knee osteoarthritis + obesity), Lilly now has two successful Phase 3 readouts in the books. Since then, TRIUMPH-2 (obesity + type 2 diabetes) and TRIUMPH-3 (obesity + established cardiovascular disease) reported on July 23, 2026, and the full TRIUMPH-1 paper appeared in the New England Journal of Medicine on September 29, 2026.

Retatrutide Phase 3 Results: What TRIUMPH-1 Measured

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight who had at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or osteoarthritis) but no diabetes. The trial randomized them 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo, all delivered as a once-weekly subcutaneous injection. The primary endpoint was percent change in body weight at 80 weeks.

Baseline characteristics: average weight 248.5 lbs, average BMI 40.0 kg/m². Dose escalation was step-wise every four weeks, starting at 2 mg and climbing in increments to the target dose. A pre-specified extension carried 532 participants (those with baseline BMI of 35 or higher who tolerated their assigned dose) out to 104 weeks total, with a blinded escalation to maximum tolerated dose.

The Headline Numbers

At the primary 80-week endpoint (efficacy estimand, i.e. people who stayed on treatment; counting everyone randomized, the figures were 17.6%, 23.7% and 25.0% vs 3.9% on placebo):

Dose
Body-weight change
Absolute loss
% achieving ≥25%
% achieving ≥30%
% achieving ≥35%
Placebo
-2.2%
-5.5 lbs
2.2%
0.5%
0.3%
4 mg
-19.0%
-47.2 lbs
27.8%
15.3%
5.9%
9 mg
-25.9%
-64.4 lbs
52.9%
37.9%
20.8%
12 mg
-28.3%
-70.3 lbs
62.5%
45.3%
27.2%
Placebo
Body-weight change
-2.2%
Absolute loss
-5.5 lbs
% achieving ≥25%
2.2%
% achieving ≥30%
0.5%
% achieving ≥35%
0.3%
4 mg
Body-weight change
-19.0%
Absolute loss
-47.2 lbs
% achieving ≥25%
27.8%
% achieving ≥30%
15.3%
% achieving ≥35%
5.9%
9 mg
Body-weight change
-25.9%
Absolute loss
-64.4 lbs
% achieving ≥25%
52.9%
% achieving ≥30%
37.9%
% achieving ≥35%
20.8%
12 mg
Body-weight change
-28.3%
Absolute loss
-70.3 lbs
% achieving ≥25%
62.5%
% achieving ≥30%
45.3%
% achieving ≥35%
27.2%

At the 104-week extension endpoint (baseline weight 268.3 lbs, BMI 42.8):

Dose
Body-weight change at 104 wks
Absolute loss
Placebo → MTD
-19.2%
-49.9 lbs
4 mg → MTD
-27.9%
-73.3 lbs
9 mg → MTD
-29.5%
-80.7 lbs
12 mg → MTD
-30.3%
-85.0 lbs

The single most quoted number from today's release will be the 30.3% figure at 104 weeks. That puts retatrutide in territory previously associated only with bariatric surgery (which produces 25 to 35% weight loss depending on procedure type, per the JAMA Surg 2014 NIH symposium Lilly cited in the press release).

Safety and Side Effects: What Stood Out

The safety profile is consistent with prior retatrutide trials and the broader GLP-1 class. GI symptoms dominated, scaled with dose:

Side effect
4 mg
9 mg
12 mg
Placebo
Nausea
28.6%
38.4%
42.4%
14.8%
Diarrhea
25.2%
34.1%
32.0%
13.5%
Constipation
23.8%
25.9%
26.1%
10.9%
Vomiting
10.6%
22.8%
25.3%
4.8%
Dysesthesia
5.1%
12.3%
12.5%
0.9%
Discontinuation (AE)
4.1%
6.9%
11.3%
4.9%
Nausea
4 mg
28.6%
9 mg
38.4%
12 mg
42.4%
Placebo
14.8%
Diarrhea
4 mg
25.2%
9 mg
34.1%
12 mg
32.0%
Placebo
13.5%
Constipation
4 mg
23.8%
9 mg
25.9%
12 mg
26.1%
Placebo
10.9%
Vomiting
4 mg
10.6%
9 mg
22.8%
12 mg
25.3%
Placebo
4.8%
Dysesthesia
4 mg
5.1%
9 mg
12.3%
12 mg
12.5%
Placebo
0.9%
Discontinuation (AE)
4 mg
4.1%
9 mg
6.9%
12 mg
11.3%
Placebo
4.9%

Three things worth flagging:

  • 4 mg discontinuation rate is below placebo. 4.1% vs 4.9%. That's unusual and points to the dose escalation schedule being the dominant driver of dropouts, not the drug itself. The 4 mg arm reaches it in one step from 2 mg.
  • Dysesthesia at 9 and 12 mg was lower than what TRIUMPH-4 reported. TRIUMPH-1 showed 12.5% at 12 mg vs the 20.9% TRIUMPH-4 figure. Lilly notes it was generally mild to moderate and most participants stayed on treatment.
  • UTI incidence was modestly elevated (7.5 to 8.8% on retatrutide vs 5.3% on placebo). Not in the FDA black box class, but worth flagging for clinicians.

For a deeper frequency-by-dose breakdown of every retatrutide side effect including management strategies, see our retatrutide side effects guide.

Retatrutide Phase 3 Results vs TRIUMPH-4, Tirzepatide and Semaglutide

TRIUMPH-1 is the obesity-only readout. TRIUMPH-4 (released December 11, 2025) studied obesity plus knee osteoarthritis and hit 28.7% weight loss at 12 mg over 68 weeks. The two are now the headline data anchors for retatrutide's regulatory package.

Drug
Trial
Population
Peak weight loss
Duration
FDA status
TRIUMPH-1 (May 2026)
Obesity, no diabetes
28.3% (12 mg, 80 wks); 30.3% (104 wks extension)
80–104 wks
Phase 3 complete; filing planned Q1 2027
Retatrutide
Obesity + knee OA
28.7% (12 mg)
68 wks
Same filing package (planned Q1 2027)
SURMOUNT-1
Obesity
22.5% (15 mg)
72 wks
FDA approved
Semaglutide (Wegovy)
STEP-1
Obesity
14.9% (2.4 mg)
68 wks
FDA approved
CagriSema
REDEFINE-1
Obesity
22.7%
68 wks
NDA filed 2026
Trial
TRIUMPH-1 (May 2026)
Population
Obesity, no diabetes
Peak weight loss
28.3% (12 mg, 80 wks); 30.3% (104 wks extension)
Duration
80–104 wks
FDA status
Phase 3 complete; filing planned Q1 2027
Retatrutide
Population
Obesity + knee OA
Peak weight loss
28.7% (12 mg)
Duration
68 wks
FDA status
Same filing package (planned Q1 2027)
Trial
SURMOUNT-1
Population
Obesity
Peak weight loss
22.5% (15 mg)
Duration
72 wks
FDA status
FDA approved
Semaglutide (Wegovy)
Trial
STEP-1
Population
Obesity
Peak weight loss
14.9% (2.4 mg)
Duration
68 wks
FDA status
FDA approved
CagriSema
Trial
REDEFINE-1
Population
Obesity
Peak weight loss
22.7%
Duration
68 wks
FDA status
NDA filed 2026

Retatrutide's TRIUMPH-1 12 mg result is among the largest average weight losses reported in a Phase 3 obesity trial (efficacy estimand; the smaller TRIUMPH-4 knee-osteoarthritis trial reported 28.7% at 12 mg on the same estimand), beating tirzepatide's SURMOUNT-1 by roughly 5.8 percentage points and semaglutide's STEP-1 by 13.4. The 30.3% figure at the 104-week extension is bigger than anything seen outside bariatric surgery. For a fuller side-by-side, see our retatrutide vs tirzepatide comparison.

What This Means for the FDA Approval Timeline

Successful Phase 3 readouts (TRIUMPH-4, TRIUMPH-1, then TRIUMPH-2 and TRIUMPH-3) put Lilly in position to file for retatrutide. The timeline as of October 2026:

  • July 23, 2026: TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) reported, and Lilly said its clinical package is complete.
  • Q1 2027: Lilly's planned Biologics License Application submission — later than first indicated, because the manufacturing (CMC) package needed more time.
  • Late 2027 at the earliest, more likely 2028: Realistic FDA decision window (about a year after submission on standard review; priority review could shorten it).
  • 2028: Realistic commercial launch window if approved on standard review.

For the most current FDA approval tracker on retatrutide see our retatrutide FDA approval timeline page.

What's Coming Next in the TRIUMPH Program

TRIUMPH-1 is part of an eight-trial Phase 3 program with over 5,800 enrolled participants. The other parts of the program:

  • TRIUMPH-2: Obesity or overweight plus type 2 diabetes. Reported July 23, 2026; full results in The Lancet on September 29, 2026 (20.8% at 12 mg, efficacy estimand).
  • TRIUMPH-3: Severe obesity with established cardiovascular disease. Reported July 23, 2026: 22.6% weight loss at 12 mg, but the heart-event analysis was inconclusive (too few events), so it can't support a heart-protection label like semaglutide's SELECT result.
  • TRIUMPH-OSA basket arms: Moderate-to-severe obstructive sleep apnea data (part of the TRIUMPH-1 basket structure).
  • TRIUMPH-KOA basket arms: Additional knee-osteoarthritis data beyond TRIUMPH-4.
  • Maintenance-dose strategies: Trials evaluating whether dose can be reduced after weight-loss targets are hit.

TRIUMPH-3's heart-event data turned out inconclusive, so whether retatrutide can be prescribed for cardiovascular prevention — which would dramatically expand the addressable patient pool and likely accelerate payer coverage — now depends on longer outcome studies.

How to Access Retatrutide Now

Retatrutide is investigational and not FDA approved. The four paths to access it in mid-2026:

  1. Clinical trial enrollment. TRIUMPH-2 and TRIUMPH-3 have finished, and no TRIUMPH trial is recruiting. As of October 2026 the only retatrutide study taking new volunteers is SYNERGY-Outcomes (liver disease); see our retatrutide clinical trials tracker.
  2. Compounding pharmacy via telehealth. Not a legal option. The FDA says retatrutide cannot be used in compounding under federal law and has warned telehealth firms and outsourcing facilities, and Lilly has sued a compounding pharmacy among other sellers.
  3. Peptide vendors. Sold without a prescription, most often as R-10 (10 mg) and R-30 (30 mg) vials. There is no medical oversight, so quality comes down to the seller's third-party testing: if you buy retatrutide this way, check the batch COA first.
  4. Wait for FDA approval. Late 2027 at the earliest, more likely 2028. Until then, Lilly runs a free, physician-led early access program for a narrow group of patients with severe obesity.

For the four-route breakdown with current pricing see how to get retatrutide in 2026 and where to buy retatrutide.

Frequently Asked Questions

When was TRIUMPH-1 announced?
Eli Lilly announced topline TRIUMPH-1 results on May 21, 2026, via press release. Lilly said full data would be presented at the 86th annual American Diabetes Association Scientific Sessions, and the full paper was published in the New England Journal of Medicine on September 29, 2026.
How much weight did people lose on retatrutide in TRIUMPH-1?
At the primary 80-week endpoint, participants on the 12 mg dose lost an average of 28.3% of body weight (70.3 lbs; efficacy estimand — 25.0% counting everyone randomized). At 9 mg they lost 25.9% (64.4 lbs), and at 4 mg they lost 19.0% (47.2 lbs). Participants with a baseline BMI of 35 or higher who continued to the 104-week extension lost up to 30.3% (85.0 lbs).
Is retatrutide better than tirzepatide?
For raw weight loss, yes. TRIUMPH-1 12 mg produced 28.3% body weight reduction at 80 weeks vs tirzepatide's SURMOUNT-1 result of 22.5% at 72 weeks (15 mg dose). The gap widens at the 104-week extension where retatrutide hit 30.3%. Tirzepatide is FDA approved and commercially available today. Retatrutide is investigational and not available outside clinical trials and Lilly's limited early access program (the FDA says it cannot be compounded). See our retatrutide vs tirzepatide comparison for the full breakdown.
When will retatrutide be FDA approved?
Lilly plans to submit its Biologics License Application in Q1 2027 (announced July 23, 2026, after TRIUMPH-2 and TRIUMPH-3 reported). A first FDA decision would realistically come in late 2027 at the earliest, more likely 2028, with commercial launch following approval.
What are the most common retatrutide side effects in TRIUMPH-1?
Gastrointestinal symptoms dominate. At the 12 mg dose: nausea 42.4%, diarrhea 32.0%, constipation 26.1%, vomiting 25.3%. Dysesthesia (skin tingling) appeared in 12.5% at 12 mg. Discontinuation due to adverse events: 11.3% at 12 mg, 6.9% at 9 mg, and 4.1% at 4 mg (below the 4.9% placebo discontinuation rate). For a fuller view see our retatrutide side effects guide.
Did the weight loss plateau or keep going in TRIUMPH-1?
It kept going. Participants on the 12 mg dose lost 28.3% at 80 weeks (the primary endpoint), then those with baseline BMI of 35 or higher who entered the 104-week extension continued to lose, hitting 30.3% (85.0 lbs) at two years. This pattern of continued weight loss past 80 weeks is one of the most clinically important findings from TRIUMPH-1.
Did TRIUMPH-1 show cardiovascular benefits?
TRIUMPH-1 was not designed to measure cardiovascular events, but secondary biomarker data showed significant improvements in waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein. TRIUMPH-3, in people with severe obesity and established cardiovascular disease, reported in July 2026: weight loss held up, but its heart-event analysis was inconclusive because there were too few events.

📚 References

  1. Eli Lilly. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." Press release, May 21, 2026. Lilly investor page
  2. Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." TRIUMPH-4 press release, December 11, 2025.
  3. TRIUMPH-1 clinical trial protocol: NCT05929066. ClinicalTrials.gov.
  4. Jastreboff AM et al. "Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial." N Engl J Med. 2023;389(6):514-526. PubMed
  5. Courcoulas AP, Yanovski SZ, Bonds D, et al. "Long-term outcomes of bariatric surgery: a National Institutes of Health symposium." JAMA Surg. 2014;149(12):1323-1329.
Medical Disclaimer: Retatrutide is an investigational drug not approved by the FDA for human therapeutic use. Information in this article is based on published clinical trial data and Eli Lilly press releases and should not be interpreted as medical advice. Do not use retatrutide for self-treatment. Always consult a qualified healthcare professional before making any medical decisions.
Retatrutide - R-30

Recommended Supplier

In StockShips from USA

Retatrutide - R-30

R-30 from Ascension Peptides, third-party tested and shipped from the US.

$125.00$250.00Save $125.00

Exclusive 50% off — use code PEPTIDEDECK

Related Topics

retatrutidetriumph-1weight-lossglp-1clinical-trialpeptide-researchobesitytriple-agonistphase-3